SUBSCRIBE
IQVIA Blog Digest
For all the latest industry insights, please subscribe to the IQVIA U.S. blog digest.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Life Sciences Solutions
-
Healthcare Solutions
-
Medical Device and Diagnostic
-
U.S. Government
Life Sciences Solutions
Bringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreLife Sciences Solutions
Healthcare Solutions
Accelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreHealthcare Solutions
Medical Device and Diagnostic Solutions
Your world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn MoreMedical Device and Diagnostic Solutions
U.S. Government Solutions
For government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn MoreU.S. Government Solutions
U.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREU.S. BLOGS
Get the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MOREBlog
Support Your Clinical and Economic Value Proposition with Real World Data - Part 3 in a series
Case Studies: How can IQVIA's PharMetrics® Plus be used?
Mar 24, 2021
In part 1 and part 2 of this blog series, we shared what data can be obtained through leveraging IQVIA’s PharMetrics® Plus. In Part 3, we examine three use cases, and highlight how the E360™ technology platform can help generate important patient-level insights from the data.
Patient journey
A “patient journey” study tracks a patient across different care settings as they access the healthcare system from the initial consultation, to diagnosis, to treatment and post-treatment. A closed database helps track the sequence of care events for each patient cohort.
In one case example, an ill-defined and often misdiagnosed musculoskeletal disorder was examined to better understand the patient journey. Using PharMetrics Plus data, a complete patient journey analysis was conducted that included treatment pathways and the patient’s health-seeking behavior. The database made it possible to look at which specialties typically diagnose this disorder, what medicines are prescribed, and what are the treatment pathways. Total costs and disease-specific costs were calculated, as well as the average cost and cost by lines of therapy. Overall costs were compared with disease-related costs.
Healthcare resource utilization and cost
Healthcare resource utilization and healthcare cost measure the economic burden of disease, and hence, are of great interest to researchers in the health economics and outcomes research (HEOR) field. Health plan-based data provides a detailed view of healthcare costs in terms of paid and allowed amount and patient liabilities. From outpatient visits and medication use, a good estimate of healthcare resource utilization can be obtained.
A study, published in the Journal of Medical Economics, examined healthcare resource utilization and costs among biologic-treated psoriasis patients in the U.S. Overall cost and cost by disease severity were evaluated in this study1. PharMetrics Plus data was linked to a national dermatology electronic medical record (EMR). Eligible adult psoriasis patients were classified by disease severity using a hierarchy of available clinical measures from the EMR.
One-year outcomes included all costs (i.e., psoriasis-related outpatient, emergency department, inpatient, and pharmacy costs) and resource use. This addressed a huge gap in the published literature on healthcare resource utilization and the cost of psoriasis patients who are already treated with biologics.
Burden of disease
Burden of disease studies monitor the impact of disease on a patient, healthcare system, and/or society. The economic burden of disease is typically measured with cost incurred, resources utilized, medication used, recurrence, hospital episodes, etc.
A study on the economic and clinical burden of acute myeloid leukemia (AML), "AML episodes of Care in the U.S.," published in the Journal of Managed Care and Specialty Pharmacy2, examined the costs associated with different AML treatment episodes. It linked PharMetrics Plus data to IQVIA’s hospital claims database and looked at treatment episodes by high-intensity chemo, low-intensity chemo, and stem cell transplantation, in addition to relapse and refractory episodes. Hospitalization was a major cost driver across all episodes. This study demonstrated a substantial economic burden associated with various AML treatment episodes, especially during high-intensity induction chemotherapy, HSCT, and Relapsed and Refractory episodes.
IQVIA E360™: From data to insights using a healthcare research platform
IQVIA E360 is a proprietary data platform that seamlessly integrates the IQVIA PharMetrics Plus data, as well as other data sources. It allows for the creation of patient cohorts in real time, and the selection of the right patient groups to run feasibility studies, trial simulations, descriptive statistics, or advanced analytics.
IQVIA's PharMetrics Plus represents an important source of real world data and has supported hundreds of clients as they seek clarity on issues that arise throughout the product lifecycle, and it is increasingly supporting government agencies. The system has reliable cost and NPI linking ability, and the benefits, as noted above, have been widely published in prestigious journals.
In case you missed it, you can read Part 1 of the blog series which addresses the uses of real world data at all stages of a product lifecycle, and Part 2 of the series which presents a bit more about PharMetrics Plus data.
References
1 Murage MJ, Anderson A, Oliveria SA, Casso D, Ojeh CK, Muram TM, Merola JF, Araujo AB. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity. J Med Econ. 2018 Aug;21(8):745-754. https://pubmed.ncbi.nlm.nih.gov/29718756/
2 Pandya BJ, Chen CC, Medeiros BC, McGuiness CB, Wilson SD, Walsh EH, Wade RL. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database. J Manag Care Spec Pharm. 2020 Jul;26(7):849-859. https://pubmed.ncbi.nlm.nih.gov/32281456/
eBook: Explore Transformative RWD Sources
Discover how you can leverage RWE to accelerate study timelines, shorten time to market, cut research costs, and more. In this interactive eBook, read case examples on how key client questions were answered in various therapeutic areas and glean insights on how you can use RWD to answer challenging research questions.